• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: Q-MED SCULPTRA; IMPLANT, DERMAL, FOR AESTHETIC USE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

Q-MED SCULPTRA; IMPLANT, DERMAL, FOR AESTHETIC USE Back to Search Results
Lot Number UNKNOWN
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Macular Edema (1822); Nausea (1970); Pupillary Block (2026); Retinal Injury (2048); Scar Tissue (2060); Loss of Vision (2139); Dizziness (2194); Obstruction/Occlusion (2422); Pallor (2468); Embolism/Embolus (4438); Eye Pain (4467); Appropriate Clinical Signs, Symptoms, Conditions Term / Code Not Available (4581)
Event Type  Injury  
Manufacturer Narrative
Company comment: the serious events of central vision loss, retinal artery occlusion, retinal artery embolism, retinal ischaemia, optic atrophy, the non-serious events of eye pain, dizziness, nausea, photopsia, pupillary reflex impaired, mydriasis, papilloedema, retinal pallor, retinal oedema and retinal scar were considered expected and possibly related to the treatment.Seriousness criteria include the need for medical interventions, hospitalization and permanent damage.The likely root cause include intravascular filler injection leading to embolism, vascular occlusion and ischemic manifestations.Potential contributory factor include injection technique or underlying comorbidities hypertension, diabetes mellitus, and coronary artery disease known to cause vascular complications due to embolic mechanism.The case meets the criteria for expedited reporting to the regulatory authorities.Product note: routine investigations have been performed and provide sufficient information to assess the potential root cause and indicate a possible association to the treatment procedure.Lot number was not reported and the product could not be verified.The information in this case does not indicate a non-conforming product or malfunction.The performed investigations are therefore considered adequate and no additional investigations will be conducted.Recommendation for corrective and preventative action: sculptra-no corrective or preventive actions are deemed necessary based on the performed investigations.
 
Event Description
Case reference number (b)(4) is a literature report identified on 09-jun-2022 during literature search.This case refers to a (b)(6) female patient.This case was identified from the literature article wu cw, wu hj.Retinal artery occlusion following cosmetic injection of poly-l-lactic acid.Taiwan j ophthalmol 2021;11:317-320.Abstract: ophthalmic vascular occlusion is an infrequent but devastating complication following cosmetic facial filler injection.We report a case of developing retinal artery occlusion after poly l lactic acid (plla) injection.A (b)(6) woman with multiple chronic diseases experienced sudden central visual loss and severe ocular pain in the right eye immediately after plla injection in the temporal region.Her best corrected visual acuity in the right eye dropped from 20/20 to 20/200.Fundus photography showed marked optic disc edema, retinal artery occlusion with multiple emboli and localized retinal whitening in the territory of the blocked vessels.Spectral domain optical coherence tomography revealed localized hyperreflectivity of the inner retina and retinal edema.Fluorescein angiography showed delayed filling of the retinal arteries and absence of retinal perfusion in the affected areas.Despite prompt aggressive management of the condition with ocular massage, topical brimonidine eyedrops, and hyperbaric oxygen therapy, the patient suffered permanent visual loss due to optic atrophy.Among all the subcutaneous filler materials, plla has not been a common cause of vascular complications, especially when injected in the temporal region, as this area has not been considered dangerous in the previous literature.Practitioners should be aware of the risk of visual loss, and extra care should be given on those who originally have a higher risk for vascular complications.Introduction: we report a case who presented with sudden central visual loss after the subcutaneous filler injections of poly l lactic acid (plla) in the temporal region.The occurrence and mechanism of retinal artery occlusion after subcutaneous injection of plla are discussed.Case report: a (b)(6) woman was referred to our emergency department due to sudden onset of a central visual defect in her right eye after subcutaneous injection of plla (sculptra, valeant aesthetics (b)(6) usa) in the right temporal region for soft tissue augmentation by a beautician approximately an hour ago.She also experienced severe ocular pain, dizziness, nausea, and photopsia immediately after the injection.She had a history of hypertension and diabetes mellitus and was on regular medications for more than 10 years.In addition, she underwent percutaneous coronary intervention with stent placement 5 months ago and was on dual antiplatelet therapy for coronary artery disease.Moreover, she had received pan retinal photocoagulation and intravitreal injections of ranibizumab for her bilateral diabetic macular edema at our branch hospital.According to the latest chart record before the episode, her best corrected visual acuity (bcva) was 20/20 in both eyes.On examination in the emergency room, her bcva was 20/200 in the right eye and 20/20 in the left eye.The intraocular pressure measured by noncontact tonometer was 22 mmhg in the right eye and 24 mmhg in the left eye.There was a relative afferent pupillary defect in the right eye, and the pupil was mid dilated.No neurogenic signs such as ptosis or ophthalmoplegia were observed.Dilated fundoscopy showed marked optic disc edema and localized retinal whitening in the territory of the blocked vessels.The scattered dot retinal hemorrhage had been observed in the previous fundus image as a sign of diabetic retinopathy.Refractive plaques were seen within the arterioles superior and inferior to the right macula.Spectral domain optical coherence tomography (sd oct) revealed localized hyperreflectivity of the inner retina and retinal edema.Fluorescein angiography showed delayed filling of the retinal arteries and absence of retinal perfusion in the affected areas in the late phase.She was immediately administered ocular massage and topical brimonidine eyedrops in the emergency room under the impression of retinal artery occlusion.During admission, she received hyperbaric oxygen therapy twice daily for 5 days.Systemic steroid pulse therapy was not adopted considering the adverse effects of uncontrollable hyperglycemia in the diabetic patients.Dual antiplatelet treatment was maintained for post stent implantation status.However, her vision did not improve upon discharge.Flash visual evoked potential was arranged 3 months later for her progressive visual loss after discharge, which showed decreased amplitude and delayed p100 latency.There was no light perception in the right eye after 1 year due to optic atrophy, even though relatively preserved foveal structures were shown in the sd oct.Fundus image of the right eye after 1 year showed pale disc and retinal arteriolar attenuation are seen with residual emboli and paramacular retinal scar.Discussion: visual loss after cosmetic facial filler injection is a rare but unacceptable complication.A study reviewed 100 cases of visual loss associated with facial filler injection and revealed that the ophthalmic artery occlusion was the most common pattern, followed by central retinal artery occlusion and branch retinal artery occlusion.The most commonly accepted mechanism for iatrogenic ophthalmic vascular occlusion is accidental intra arterial injection followed by subsequent retrograde of the material from the injection site to the ophthalmic artery through the distal anastomosis between the branches.Among all the subcutaneous filler materials, autologous fat was most likely to cause vascular complications because of its larger particle size, followed by hyaluronic acid, and then other fillers such as calcium hydroxyl apatite and plla.Plla is a synthetic biodegradable polymer that provides soft tissue augmentation by stimulating an inflammatory tissue response with subsequent collagen deposition.Comparing to autologous fat (>400 m) and hyaluronic acid (~400 m), plla has a smaller particle size (40-63 ¿m).However, few cases of vascular complications after plla injection have been reported.Park et al.Reported the two cases of posterior ciliary artery occlusion; one case had an injection in the eyelid and the other in the glabella.Roberts and arthurs reported another case of ocular and orbital ischemia after periorbital injection.In addition, ragam et al.Reported ipsilateral ophthalmic and cerebral infarctions after a forehead injection.However, retinal artery occlusion after plla injections in the temporal region has not been reported.According to the previous literature, injection of filler virtually at any location on the face predisposes to blindness because the vascular supply of the face is highly variable and anastomotic.The glabella, nose, nasolabial fold, and forehead are usually considered as the high risk areas for blindness complications.In the presented case, the patient received injections in the temporal region, which is not known to be a common site for visual loss.Previous studies have reported that loss of vision is irreversible in most cases of ophthalmic vascular occlusion, and to date, no effective treatments have been developed.Conventional treatments for spontaneous central retinal artery occlusion have been applied in the iatrogenic retinal artery occlusion.However, none of them showed favorable results.In our case, despite the prompt and aggressive management of the condition, a good visual outcome was not obtained.Hypertension, diabetes mellitus, and coronary artery disease are known to be risk factors for retinal artery occlusion.As far as we know, no study has compared the incidence of ophthalmic vascular occlusion after cosmetic facial filler injection between patients with and without the aforementioned comorbidities.We consider that patients with the aforementioned comorbidities are more vulnerable to the vascular complications owing to an embolic mechanism.Hence, cosmetic injections should be administered to these patients with extra care and strict patient assessment performed beforehand.To the best of our knowledge, the retinal artery occlusion after plla injection in the temporal region has not been reported previously.Regardless of the type of filler or the injected facial region, practitioners should be cautious of the possible complication of visual loss, especially in patients with a higher risk of vascular complications.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SCULPTRA
Type of Device
IMPLANT, DERMAL, FOR AESTHETIC USE
Manufacturer (Section D)
Q-MED
seminariegatan 21
uppsala, SE-75 228
SW  SE-75228
Manufacturer (Section G)
Q-MED
seminariegatan 21
uppsala, SE-75 228
SW   SE-75228
Manufacturer Contact
randy russell
14501 n. freeway
fort worth, TX 76177
MDR Report Key14788888
MDR Text Key295105711
Report Number9710154-2022-00041
Device Sequence Number1
Product Code LMH
Combination Product (y/n)N
Reporter Country CodeTW
PMA/PMN Number
P030050/S034
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature,Health Professional
Reporter Occupation Physician
Type of Report Initial
Report Date 06/23/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/23/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received06/09/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Unknown
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Disability; Required Intervention;
Patient Age49 YR
Patient SexFemale
-
-